Register for our free email digests:
Division of Shire PLC
Latest From Baxalta Inc.
Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.
Ipsen's VP of commercial operations for the UK and Ireland outlines how the French company will use managed access programs to get drugs reimbursed on the NHS and describes Ipsen's plans for growth and greater investment in the UK, despite Brexit uncertainties.
Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Neurology, Nervous System
- Baxter BioScience
- North America
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Ludwig N Hantson, PhD, Pres. & CEO
Robert J Hombach, EVP, CF & COO
John J Orloff, MD, EVP, Head, R&D & CSO
- Contact Info
Phone: (224) 940-2000
One Baxter Pkwy.
Deerfield, IL 60015
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.